Key Details
Annual Revenue
$32.58 MAnnual EPS
-$2.33Annual ROE
-65.78%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
May 05, 2023Recent annual earnings:
Mar 03, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
20 Jan '23 JonesTrading
Hold13 Sept '22 Truist Securities
Buy25 Aug '22 JonesTrading
Buy05 Oct '21 Mizuho
Buy02 Feb '21 Truist Securities
Buy16 Dec '20 Berenberg
Buy03 Oct '19 HC Wainwright & Co.
Buy03 Oct '19 H.C. Wainwright
Buy30 Sept '19 SunTrust Robinson Humphrey
Buy30 Sept '19 Mizuho
BuyScreeners with CNCE included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Concert Pharmaceuticals doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Concert Pharmaceuticals?
- What is the ticker symbol for Concert Pharmaceuticals?
- Does Concert Pharmaceuticals pay dividends?
- What sector is Concert Pharmaceuticals in?
- What industry is Concert Pharmaceuticals in?
- What country is Concert Pharmaceuticals based in?
- When did Concert Pharmaceuticals go public?
- Is Concert Pharmaceuticals in the S&P 500?
- Is Concert Pharmaceuticals in the NASDAQ 100?
- Is Concert Pharmaceuticals in the Dow Jones?
- When was Concert Pharmaceuticals's last earnings report?
- When does Concert Pharmaceuticals report earnings?
- Should I buy Concert Pharmaceuticals stock now?
What is the primary business of Concert Pharmaceuticals?
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of March 6, 2023, Concert Pharmaceuticals, Inc. operates as a subsidiary of Sun Pharmaceutical Industries Limited.
What is the ticker symbol for Concert Pharmaceuticals?
The ticker symbol for Concert Pharmaceuticals is NASDAQ:CNCE
Does Concert Pharmaceuticals pay dividends?
No, Concert Pharmaceuticals does not pay dividends
What sector is Concert Pharmaceuticals in?
Concert Pharmaceuticals is in the Healthcare sector
What industry is Concert Pharmaceuticals in?
Concert Pharmaceuticals is in the Biotechnology industry
What country is Concert Pharmaceuticals based in?
Concert Pharmaceuticals is headquartered in United States
When did Concert Pharmaceuticals go public?
Concert Pharmaceuticals's initial public offering (IPO) was on 13 February 2014
Is Concert Pharmaceuticals in the S&P 500?
No, Concert Pharmaceuticals is not included in the S&P 500 index
Is Concert Pharmaceuticals in the NASDAQ 100?
No, Concert Pharmaceuticals is not included in the NASDAQ 100 index
Is Concert Pharmaceuticals in the Dow Jones?
No, Concert Pharmaceuticals is not included in the Dow Jones index
When was Concert Pharmaceuticals's last earnings report?
Concert Pharmaceuticals's most recent earnings report was on 5 May 2023
When does Concert Pharmaceuticals report earnings?
The date for Concert Pharmaceuticals's next earnings report has not been announced yet
Should I buy Concert Pharmaceuticals stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions